Moderna COVID-19 Vaccine

From GM-RKB
(Redirected from mRNA-1273)
Jump to navigation Jump to search

A Moderna COVID-19 Vaccine is a COVID-19 Vaccine that is a lipid nanoparticle–encapsulated mRNA-based vaccine discovered by Moderna researchers.



References

2021

  • (Rose et al., 2021) ⇒ Nicole Doria-Rose, Mehul S. Suthar, Mat Makowski, Sarah O’Connell, Adrian B. McDermott, Britta Flach, Julie E. Ledgerwood et al. (2021). “Antibody Persistence through 6 Months After the Second Dose of MRNA-1273 Vaccine for Covid-19.” New England Journal of Medicine 384, no. 23
    • ABSTRACT: ... Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1 The durability of protection is currently unknown. We describe mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adult participants in an ongoing phase 1 trial,2-4 stratified according to age, at 180 days after the second dose of 100 μg (day 209).

      Antibody activity remained high in all age groups at day 209. Binding antibodies, measured by means of an enzyme-linked immunosorbent assay against SARS-CoV-2 spike receptor–binding domain,2 had geometric mean end-point titers (GMTs) of 92,451 (95% confidence interval [CI], 57,148 to 149,562) in participants 18 to 55 years of age, 62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age, and 49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older.

2021

2021